Archive: September, 2015

 

 

Avita Medical Awarded US Government Contract valued at up to $53. 9 m USD

BARDA contract commits initial USD16.9m to support Avita’s FDA approval trial for treatment of thermal burn injuries and procure 5000-plus ReCell® devices.

Read more about Avita Medical Awarded US Government Contract valued at up to $53. 9 m USD

Nexvet Receives FY2015 Cash Refund of $3.2 Million

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced receipt of US$3.2 million in cash under the Australian Federal Government’s Research and Development (R&D) Tax Incentive program. This program provides a 45 percent refundable tax offset for qualifying R&D in Australia, where Nexvet conducts its drug discovery activities, including PETization™.

Read more about Nexvet Receives FY2015 Cash Refund of $3.2 Million

SeaDragon raises $10.009 million

SeaDragon raises $10.009 million via rights offer and shortfall bookbuild, and additional placement.

Read more about SeaDragon raises $10.009 million

Rex Bionics Plc notes two legal cases awarding insurance funding for wheelchair user access to the REX robotic walking device

Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, notes two recent legal settlements — awarding funding for the purchase of a REX robot and funding for Robot-Assisted Physiotherapy with REX.

Read more about Rex Bionics Plc notes two legal cases awarding insurance funding for wheelchair user access to the REX robotic walking device

Nexvet Secures Biomanufacturing Facility and Receives IDA Ireland Support

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced it has secured a dedicated biologics manufacturing facility in Tullamore, Ireland. The transaction is supported by the Irish Government’s Department of Jobs, Enterprise & Innovation through IDA Ireland, their foreign investment agency.

Read more about Nexvet Secures Biomanufacturing Facility and Receives IDA Ireland Support